A medical odyssey of a 72‐year‐old man with Charcot–Marie–Tooth disease type 2 newly diagnosed with biallelic variants in SORD gene causing sorbitol dehydrogenase deficiency
Authors:
- Yutaka FurutaYFYutaka Furuta
- The Undiagnosed Diseases NetworkTNThe Undiagnosed Diseases Network
- 25 August 2023
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 191 (12) , 2873-2877
Abstract
A 72‐year‐old man was referred to the Undiagnosed Diseases Network (UDN) because of gradual progressive weakness in both lower extremities for the past 45 years. He was initially diagnosed as having Charcot–Marie–Tooth disease type 2 (CMT2) without a defined molecular genetic cause. Exome sequencing (ES) failed to detect deleterious neuromuscular variants. Very recently, biallelic variants in sorbitol dehydrogenase (SORD) were discovered to be a novel cause of inherited neuropathies including CMT2 or distal hereditary motor neuropathy (dHMN) referred to as Sorbitol Dehydrogenase Deficiency with Peripheral Neuropathy (SORDD, OMIM 618912). The most common variant identified was c.757delG; p.A253Qfs*27. Through the Vanderbilt UDN clinical site, this patient was formally diagnosed with SORDD after the identification of homozygosity for the above SORD frameshift through UDN Genome Sequencing (GS). His medical odyssey was solved by GS and detection of extremely high levels of sorbitol. The diagnosis provided him the opportunity to receive potential treatment with an investigational drug in a clinical trial for SORDD. We suggest that similar studies be considered in other individuals thought to possibly have CMT2 or dHMN.Keywords
Funding Information
- Common Fund
- National Human Genome Research Institute (9U01NS134349‐10)
This publication has 8 references indexed in Scilit:
- Emerging Therapies for Charcot-Marie-Tooth Inherited NeuropathiesInternational Journal of Molecular Sciences, 2021
- Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patientsScientific Reports, 2021
- Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetesNature Genetics, 2020
- Comparison of clinical parameters with whole exome sequencing analysis results of autosomal recessive patients; a center experienceMolecular Biology Reports, 2018
- Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double‐blind placebo‐controlled study in JapanJournal of Diabetes Investigation, 2018
- CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysisJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Charcot–Marie–Tooth disease: frequency of genetic subtypes and guidelines for genetic testingJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral NeuropathyDiabetes Care, 2006